Prophylactic efficacy of carbamazepine in manic-depressive illness
Abstract
Seven patients with rapidly cycling, lithium-resistant affective illness were followed for an average of 1.7 years during prophylactic treatment with carbamazepine administered on either a blind or an open basis. The number of manic and depressive episodes per year decreased significantly--from 16.4 before treatment to 5.6 during carbamazepine treatment; severity and duration of episodes were also reduced. Six of seven patients relapsed after carbamazepine dose reduction or discontinuation. These preliminary data add further support to the growing evidence that carbamazepine may be useful in the acute and prophylactic treatment of some lithium-resistant patients.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
